ArticlePDF Available

Green Tea and One of Its Constituents, Epigallocatechine-3-gallate, Are Potent Inhibitors of Human 11β-hydroxysteroid Dehydrogenase Type 1


Abstract and Figures

The microsomal enzyme 11β-hydroxysteroid deydrogenase type 1 (11β-HSD1) catalyzes the interconversion of glucocorticoid receptor-inert cortisone to receptor- active cortisol, thereby acting as an intracellular switch for regulating the access of glucocorticoid hormones to the glucocorticoid receptor. There is strong evidence for an important aetiological role of 11β-HSD1 in various metabolic disorders including insulin resistance, diabetes type 2, hypertension, dyslipidemia and obesity. Hence, modulation of 11β-HSD1 activity with selective inhibitors is being pursued as a new therapeutic approach for the treatment of the metabolic syndrome. Since tea has been associated with health benefits for thousands of years, we sought to elucidate the active principle in tea with regard to diabetes type 2 prevention. Several teas and tea specific polyphenolic compounds were tested for their possible inhibition of cortisone reduction with human liver microsomes and purified human 11β-HSD1. Indeed we found that tea extracts inhibited 11β-HSD1 mediated cortisone reduction, where green tea exhibited the highest inhibitory potency with an IC50 value of 3.749 mg dried tea leaves per ml. Consequently, major polyphenolic compounds from green tea, in particular catechins were tested with the same systems. (-)-Epigallocatechin gallate (EGCG) revealed the highest inhibition of 11β-HSD1 activity (reduction: IC50 = 57.99 µM; oxidation: IC50 = 131.2 µM). Detailed kinetic studies indicate a direct competition mode of EGCG, with substrate and/or cofactor binding. Inhibition constants of EGCG on cortisone reduction were Ki = 22.68 µM for microsomes and Ki = 18.74 µM for purified 11β-HSD1. In silicio docking studies support the view that EGCG binds directly to the active site of 11β-HSD1 by forming a hydrogen bond with Lys187 of the catalytic triade. Our study is the first to provide evidence that the health benefits of green tea and its polyphenolic compounds may be attributed to an inhibition of the cortisol producing enzyme 11β-HSD1.
Content may be subject to copyright.
Green Tea and One of Its Constituents,
Epigallocatechine-3-gallate, Are Potent Inhibitors of
Human 11b-hydroxysteroid Dehydrogenase Type 1
Jan Hintzpeter, Claudia Stapelfeld, Christine Loerz, Hans-Joerg Martin, Edmund Maser*
Institute of Toxicology and Pharmacology for Natural Scientists, University Medical School Schleswig-Holstein, Campus Kiel, Germany
The microsomal enzyme 11b-hydroxysteroid deydrogenase type 1 (11b-HSD1) catalyzes the interconversion of
glucocorticoid receptor-inert cortisone to receptor- active cortisol, thereby acting as an intracellular switch for regulating
the access of glucocorticoid hormones to the glucocorticoid receptor. There is strong evidence for an important aetiological
role of 11b-HSD1 in various metabolic disorders including insulin resistance, diabetes type 2, hypertension, dyslipidemia and
obesity. Hence, modulation of 11b-HSD1 activity with selective inhibitors is being pursued as a new therapeutic approach
for the treatment of the metabolic syndrome. Since tea has been associated with health benefits for thousands of years, we
sought to elucidate the active principle in tea with regard to diabetes type 2 prevention. Several teas and tea specific
polyphenolic compounds were tested for their possible inhibition of cortisone reduction with human liver microsomes and
purified human 11b-HSD1. Indeed we found that tea extracts inhibited 11b-HSD1 mediated cortisone reduction, where
green tea exhibited the highest inhibitory potency with an IC50 value of 3.749 mg dried tea leaves per ml. Consequently,
major polyphenolic compounds from green tea, in particular catechins were tested with the same systems. (2)-
Epigallocatechin gallate (EGCG) revealed the highest inhibition of 11b-HSD1 activity (reduction: IC50 = 57.99 mM; oxidation:
IC50 = 131.2 mM). Detailed kinetic studies indicate a direct competition mode of EGCG, with substrate and/or cofactor
binding. Inhibition constants of EGCG on cortisone reduction were Ki = 22.68 mM for microsomes and Ki = 18.74 mM for
purified 11b-HSD1. In silicio docking studies support the view that EGCG binds directly to the active site of 11b-HSD1 by
forming a hydrogen bond with Lys187 of the catalytic triade. Our study is the first to provide evidence that the health
benefits of green tea and its polyphenolic compounds may be attributed to an inhibition of the cortisol producing enzyme
Citation: Hintzpeter J, Stapelfeld C, Loerz C, Martin H-J, Maser E (2014) Green Tea and One of Its Constituents, Epigallocatechine-3-gallate, Are Potent Inhibitors
of Human 11b-hydroxysteroid Dehydrogenase Type 1. PLoS ONE 9(1): e84468. doi:10.1371/journal.pone.0084468
Editor: Kang Sun, Fudan University, China
Received August 13, 2013; Accepted November 21, 2013; Published January 3, 2014
Copyright: ß2014 Hintzpeter et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Work on 11b-HSD1 in our laboratory is funded by the German Federal Ministry of Education and Research (0315397A) and the Deutsche
Forschungsgemeinschaft (MA 1704/5-2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
Competing Interests: The authors have declared that no competing interests exist.
* E-mail:
Tea (Camellia sinensis) is the second most widely consumed
beverage in the world after water [1] and has been cultivated for
thousands of years due to its medicinal benefits and general health
promotion purposes.
The tea plant is naturally occurring in South China, but is
nowadays cultivated in many other regions of the major tea
producing countries in the world, like India, Japan, Sri Lanka,
Indonesia and Kenia. In general, tea can be divided into three
types (percentage of worlds tea production): non-fermented green
tea (20%), semi-fermented tea (e.g. oolong tea and white tea) (2%)
and fermented black tea (78%) [2]. Additionally, there are more
than 300 different kinds of tea that differ regarding the
manufacturing process.
The most popular form of tea consumed in the world is black
tea, whereas green tea is mainly consumed in China and Japan.
Recently, plenty of commercial beverages came to market that
contain tea extracts or catechins from tea. Nowadays, tea or
beverages containing tea extracts, if consumed daily, belong to a
life-style that might support healthiness and long life, which is
underpined by several laboratory, epidemiological and human
intervention studies [3–7].
In particular, consumption of green tea has been associated with
a reduction of the risk of cardiovascular disease, some forms of
cancer, as well as with the promotion of oral health and other
physiological functions such as antibacterial and antiviral activity,
neuroprotective properties, anti-hypertensive effects, body weight
control and diabetes type 2 prevention [8,9].
The latter diseases are risk factors of the metabolic syndrome
(obesity, insulin resistance, hypertension, diabetes type 2, dyslipi-
demia) against which the therapeutical potential of tea has been
shown in humans and model organisms in numerous studies [10–
In most cases the beneficial effects have been attributed to the
polyphenolic compounds, especially catechins, although a large
number of potentially bioactive chemicals are present in tea as well
[15]. (2)-Epigallocatechin-3-gallate (EGCG) is the major compo-
nent among the tea catechins and is believed to have a
considerable therapeutical potential [16].
PLOS ONE | 1 January 2014 | Volume 9 | Issue 1 | e84468
Unlike semi-fermented and fermented teas (black and white
teas) unfermented green tea contains more catechins [17]. A
typical green tea infusion of 250 ml hot water with 2.5 g tea leaves
approximately contains 620–880 mg of water-extractable solid
compounds. About 30–42% of the dry weight of green tea consists
of phenolic compounds [18,19], from which EGCG is the most
abundant one (up to 50–80% of the total catechins [18]).
Other catechins are present in smaller amounts: (2)-epigallo-
catechin (EGC).(2)-epicatechin gallate (ECG).(2)-epicatechin
(EC).gallocatechin gallate (GCG).gallocatechin (GC).cate-
chin gallate (CG).catechin (C).epigallocatechin digallate .
epicatechin digallate [18].
Many other components have been identified in tea that might
have an effect on human health: theaflavins, thearubigins,
theasinesins, gallic acid, quinic acid, theogallin, coumaryl-quinic
acid, caffeine, theobromine and theophylline, L-theanine (unique
to tea), kaempferol, myricetin and quercetin [2,17].
It has been estimated that up to one-third of patients with
diabetes type 2, hypertension and dyslipidaemia consume some
form of complementary and alternative medicine, involving the
use of herbs and other dietary supplements, like plant infusions, as
alternatives to mainstream Western medical treatment [20]. For
this reason, our lab is in search of herbs that are traditionally used
for the treatment of symptoms of the metabolic syndrome in the
medicine of several indigenous populations as well as in traditional
Chinese medicine. In comparison with high-throughput screening
of large chemical libraries to discover new drugs, medical
treatments of chronic diseases by traditional Chinese medicine
and indigenous populations feature clear benefits based on their
thousand-year-old experience in dealing with some of the above
mentioned chronic diseases [21].
In humans high levels of intracellular cortisol can increase
glucose output in the liver, induce fat accumulation and weaken
insulin sensitivity in adipose tissues, resulting in an increased risk
for the metabolic syndrome [22]. Cortisol-levels are regulated by
two known isoforms of 11b-hydroxysteroid dehydrogenase (see
Figure 1): a microsomal NADPH-dependent 11b-hydroxysteroid
dehydrogenase type 1 (11b-HSD1) primarily acting as a reductase
in liver, fat tissues, lung and macrophages and a NAD dependent
11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) that is
expressed in kidney, salivary glands, colon and placenta. 11b-
HSD2 is a unidirectional oxidase that deactivates glucocorticoid-
receptor active cortisol to cortisone [23–26].
Multiple evidence argues for an important aetiological role of
11b-HSD1 in various metabolic disorders including insulin
resistance or rather diabetes type 2, hypertension, dyslipidaemia
and obesity [22,27–31]. 11b-HSD1-deficient mice show enhanced
glucose tolerance, improved hepatic insulin resistance, attenuated
gluconeogenesis, and an improved lipid and lipoprotein profile
[32–34]. Moreover, overexpression of 11b-HSD1 selectively in
adipose tissue causes visceral obesity, insulin resistance, type 2
diabetes, dyslipidemia, and hypertension in mice [22].
Collectively, these findings emphasize the potential benefits of a
specific inhibitor of human 11b-HSD1 in the treatment of obesity
and type 2 diabetes. In the present investigation, we tested several
teas and some major tea-specific polyphenolic compounds,
catechins, for their capability to inhibit the cortisol producing
enzyme 11b-HSD1. Inhibition of 11b-HSD1 would shed light on
– at least some of – the mechanisms by which green tea performs
its health effect.
Materials and Methods
Ethics Statement
Work on pluripotent carbonyl reductases/hydroxysteroid de-
hydrogenases, including 11b-HSD1, was approved by the ethics
commission of the Medical Faculty, University of Kiel. Human
liver tissue was obtained with written informed consent and
approval by ethics commission of the Medical Faculty, University
of Kiel. All experimental studies were performed in accordance
with German legislation.
Cortisol, cortisone and EGCG were purchased from Sigma-
Aldrich (St. Louis, MO). The following chemicals were procured
from Carl Roth GmbH +Co. KG (Karlsruhe, Germany):
Ethylacetate, NADP, NADPH, non-fat dry milkpowder, mono-
sodium phosphate and potassium chloride, HPLC column
LiChrospherH100 RP-18, methanol, sodium chloride and
monopotassium phosphate were obtained from Merck (Darmstadt,
Germany). (2)-Epicatechin gallate, (2)-catechin and (2)-galloca-
techin were purchased from Biomol GmbH (Hamburg, Germany),
Cayman Chemical (Ann Arbor, MI) and LKT Laboratories Inc.
(St. Paul, MN), respectively. The different types of commercially
available teas consisting of green, oolong and black teas were
bought from supermarkets in Kiel, Germany. The anti-HSD11B1
antibody (ab83522) was obtained from Abcam (Cambridge, UK).
Preparation of tea extracts
Dried tea leaves were reduced to small pieces and 1 g of the
crushed material was suspended in 10 mL water without stirring
for 90 min at room temperature. Insoluble material was removed
by centrifugation (13,000 RPM in a microcentrifuge) and the
resulting supernatant was used in enzyme inhibition experiments.
Preparation of 11b-HSD1-containing microsomes and
purification of human 11b-HSD1
Human liver microsomes and purified human 11b-HSD1 were
prepared as described previously [35,24].
Enzyme assay
In terms of 11b-HSD1 reductase activity, inhibition analysis was
performed as follows: 50 ml of tea extract were added to a mixture
containing 400 mM cortisone, 0.8 mM NADPH solution in
100 mM phosphate buffer pH 7.4. The reaction was started by
adding 5 ml of human liver microsomes (218 mg protein) and the
mixture was incubated for 3 h at 37uC. The total assay volume
was 250 ml.
The reaction was stopped by adding 250 ml ice-cold ethylacetate
and vortexing, followed by a 30 sec centrifugation at 13,000 RPM
in a microcentrifuge. The organic phase was separated and the
aqueous phase extracted two more times with 250 ml ethylacetate.
The ethylacetate phases were combined and the solvent was
removed in a SpeedVac (ThermoSavant). The resulting residue
was dissolved in 150 ml methanol-water (58:42, v/v) and used for
metabolite quantification by HPLC.
To analyze inhibition of 11b-HSD1 dehydrogenase activity, the
oxidation of cortisol to cortisone was measured essentially as
described above, except for the substitution of NADPH with
0.8 mM NADP, and the use of 400 mM cortisol instead of
cortisone. Here, the incubation time was 60 min at 37uCina
100 mM phosphate buffer pH 9.0.
11b-HSD1 Inhibition by Green Tea and EGCG
PLOS ONE | 2 January 2014 | Volume 9 | Issue 1 | e84468
Metabolite quantification by HPLC
After enzymatic conversion the glucocorticoids were resolved as
published previously [36]. Product yield was quantified by peak
integration of the cortisone and cortisol peaks, respectively.
Determination of the mode of 11b-HSD1 inhibition by
EGCG and of its inhibition constant Ki
The type of inhibition by EGCG (dissolved in buffer solution)
was determined with four inhibitor (0, 20, 50, 75, 100 mM EGCG)
and substrate (50, 100, 200, 400 mM cortisone) concentrations.
The data obtained were plotted as substrate-velocity curves and
analyzed by nonlinear-regression. The type of inhibition was
tested with both human liver microsomes (218 mg) and purified
11b-HSD1 (16.4 mg).
Western Blot analysis after EGCG incubation with
microsomal and purified 11b-HSD1
To exclude EGCG-induced 11b-HSD1 aggregate formation,
purified 11b-HSD1 (2.14 mg) was preincubated with 25–100 mM
EGCG (3 h at 37uC) and then prepared for sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) according to the
manufacturer’s protocol. As a control, the same volume of
untreated purified protein was loaded onto the parallel lane.
The resolved proteins were transferred to nitrocellulose
membranes. After blocking the membrane for 1 h at RT with
5% non-fat dry milkpowder in PBS-buffer, the blocking solution
was replaced by the primary antibody at a 1:2,000 dilution and the
membrane was incubated at 4uC for about 16 h. Primary and
secondary antibodies were diluted in PBS containing 2.5% non-fat
dry milkpowder. The membrane was washed three times and then
the corresponding secondary antibody was added at a dilution of
1:10,000. After a 1.5 h incubation at RT the membrane was
washed three times and the specific Western blot signals of 11b-
HSD1 were detected by the ECL Western Blotting System
according to the manufacturer’s instructions.
Quantification of hydrogen peroxide by xylenol orange
According to Halliwell [37] and Lay et al. [38], EGCG induces
hydrogen peroxide production in various buffer systems. For this
reason, we determined the hydrogen peroxide concentration
produced by EGCG (concentration 200 mM) after 3 h incubation
at 37uC either in the buffer used or in our complete assay systems
[39]. Further, to exclude any inhibitory effects of hydrogen peroxide
on cortisone reduction, we tested the influence of hydrogen peroxide
on cortisol production by HPLC (as described above) with both
human liver microsomes and purified 11b-HSD1, respectively.
Figure 1. Physiological role of the two isoenzymes 11b-HSD type 1 and 2. Predominant reaction direction of the NADP(H)-dependent
enzyme 11b-HSD1 by catalyzing the conversion of inactive cortisone to receptor-active cortisol. The reverse reaction is mediated by the unidirectional
NAD-dependent 11b-HSD type 2.
Figure 2. Inhibition of cortisone reduction by three different
types of tea (Green, Black and White Tea) in human liver
microsomes. Product yields were quantified by integration of cortisol
peaks. The product yields of the controls without any type of tea were
normalized to 100% enzyme activity and the residual activity expressed
as percent of the control. Bars represent the mean 6SD of at least three
repeat experiments.
Figure 3. Dose-dependent inhibition of cortisone reduction by
green tea in human liver microsomes. Results are presented as
means ±SD (n = 4).
11b-HSD1 Inhibition by Green Tea and EGCG
PLOS ONE | 3 January 2014 | Volume 9 | Issue 1 | e84468
Concentration-dependent inhibition of cortisol
production by three types of tea in human liver
Inhibition of 11b-HSD1 activity was assessed by determining
cortisol yields after 3 h incubation at 37uC with equal volumes of
green, black and white tea infusions (100 mg tea per ml; prepared
as described above). Quantification was performed by integration
of the well-resolved product peaks in the above discribed HPLC
assay. Figure 2 shows the inhibitory effects of three commercially
available teas on human microsomal 11b-HSD1 reductase
activity. Conversion of cortisone to cortisol was inhibited by all
three types of tea in a concentration-dependent manner, with
green tea exhibiting the highest inhibition.
Figure 5. Chemical structures of five green tea catechins used in this study. EGCG, (2)-epigallocatechin-3-gallate; EGC, (2)-
epigallocatechin; EC, (2)-epicatechin; GC, (2)-gallocatechin; C, (2)-catechin.
Figure 4. Inhibitory effects of five tea catechins on cortisone reduction in human liver microsomes. Bars represent the mean 6SD of at
least three repeat experiments.
11b-HSD1 Inhibition by Green Tea and EGCG
PLOS ONE | 4 January 2014 | Volume 9 | Issue 1 | e84468
Concentration-dependent inhibition of cortisol
production by green tea in human liver microsomes
As shown in Figure 2, green tea extract displayed the highest
inhibitory potency of the three types of tea tested. With human
liver microsomes and different amounts of green tea extract a
dose-response inhibition curve of microsomal cortisone reduction
was observed. An IC50-value of 3.75 mg crushed dried tea leaves
per ml (this corresponds to a value of 0.75 vol% of green tea
extract in the reaction mixture) was determined (Fig. 3).
Inhibition of cortisol production by several constituents
of green tea in human liver microsomes
Inhibition of cortisone reduction in human liver microsomes
was assessed with several green tea constituents. Figure 4 shows the
residual enzymatic activity after incubation with five catechins
found in green tea (see Fig. 5) measured at three concentrations.
Highest inhibition was achieved with EGCG, followed by GC
(gallocatechin). The half maximal inhibitory concentration (IC50)
determined for EGCG on 11b-HSD1 activity in microsomes was
57.99 mM (Figure 6). It should be noted that an aqueous solution
of EGCG, when stored at 220uC for one week, resulted in an
IC50-value about half as high (26.88 mM) as that determined with
freshly prepared EGCG solutions.
To determine possible differences in the potential of EGCG to
inhibit reductase and dehydrogenase activity of 11b-HSD1, the
influence of EGCG on the oxidation of cortisol to cortisone was
monitored. Figure 7 shows the EGCG concentration-dependent
decrease of 11b-HSD1 cortisol dehydrogenase activity in micro-
somes. From these data an IC50-value of 131.20 mM was
Determination of the type of inhibition by EGCG and of
its dissociation constant Ki with human liver microsomes
and purified 11b-HSD1
To determine the mechanism of 11b-HSD1 inhibition by
EGCG various inhibitor and substrate concentrations were used.
Non-linear regression analysis yielded Ki -values of
Ki = 22.68610.10 mM and Ki = 18.7468.00 mM for microsomes
and the purified enzyme, respectively (Insets Figs. 8,9 and Table 1).
The data were best fitted using a model of mixed inhibition. In line
with this calculation were the results of the Dixon-plots
(Figures 8,9). The regression lines converge above the abscissa
indicating a competetive or mixed mode of inhibition and Ki -
values similar to those obtained by non-linear regression (Table 1).
Western Blot analysis after EGCG incubation with purified
As shown in Figure 10, EGCG preincubation (3 h at 37uC) with
purified 11b-HSD1 did not induce protein aggregate formation.
No differences in the treated (lane 2–4) and untreated samples
(lane 1) of purified 11b-HSD1 were observed, even at EGCG
concentrations up to 100 mM.
Quantification of EGCG generated hydrogen peroxide by
xylenol orange
When 200 mM EGCG was incubated for 3 h at 37uC in buffer
only (same buffer as used in our assays above), the formation of
220 mM hydrogen peroxide was determined by the xylenol orange
assay. However, when human liver microsomes, NADPH and
cortisone was added (in the same concentrations as in the enzyme
assays), only 12 mM hydrogen peroxide could be detected.
Further, we tested the influence of up to 300 mM hydrogen
peroxide on cortisol production with both human liver micro-
somes and purified human 11b-HSD1, respectively. No 11b-
HSD1 inhibition by hydrogen peroxide could be detected (data
not shown).
Tea infusions have not only been a popular beverage for
thousands of years but also have been traditionally used for the
treatment of the metabolic syndrome and other chronic diseases.
The metabolic syndrome is a complex metabolic disorder that may
lead to diabetes type 2 and is one of the fastest growing diseases
within the western civilisation. The role of glucocorticoid
hormones in maintaining the blood glucose level by mobilization
of energy sources is essential for homeostasis: Cortisol deficiency
results in low blood glucose levels, dizziness, generalized weakness
and stress sensitivity while cortisol overproduction, hypercortisol-
ism, leads to high blood pressure, increased abdominal fat
deposition, insulin resistance etc. Due to its pivotal role in cortisol
production, inhibition of 11b-HSD1 maybe of therapeutic value in
the treatment of the metabolic syndrome and diabetes.
For these reasons our laboratory has investigated the inhibitory
effects of tea, in particular green tea and some of its constitutents,
on microsomal and purified 11b-HSD1 mediated cortisone
reductase (and cortisol dehydrogenase) activity. The present study
demonstrates that tea and green tea, respectively, and some of
their polyphenolic constituents, EGCG and GC, have the
capability to inhibit human 11b-HSD1.
Figure 6. Dose-dependent inhibition of cortisone reduction by
EGCG in human liver microsomes. Results are presented as means
6SD (n = 4).
Figure 7. Dose-dependent inhibition of cortisol oxidation by
EGCG in human liver microsomes. Results are presented as means
6SD (n = 4).
11b-HSD1 Inhibition by Green Tea and EGCG
PLOS ONE | 5 January 2014 | Volume 9 | Issue 1 | e84468
Initially, we could show that non-fermented green tea, semi-
fermented tea (e.g. oolong tea and white tea) and fermented black
tea have different potencies to inhibit human 11b-HSD1 mediated
cortisone reduction. Non-fermented green tea showed the highest
inhibitory potential (IC50 of 3.75 mg crushed dried tea leaves per
ml, which corresponds to a value of 0.75 vol% of green tea
extract), whereas a weaker inhibition potency was observed by
semi-fermented white and fermented black tea.
A reason for higher 11b-HSD1 inhibition by green tea
compared to other teas might be a higher concentration of
phenolic compounds in the former. During the fermentation
process phenolic compounds, like catechins, are enzymatically
oxidized. To protect the polyphenolic compounds from enzymatic
oxidation, tea leaves that are destined to become green tea are
withered by air drying prior to heat inactivation of polyphenol
Consequently, we tested several polyphenolic compounds
known from green tea, in particular catechins, for their inhibition
of 11b-HSD1 cortisone reduction. Interestingly, we observed big
differences in the inhibition potency among the structurally related
catechins (see Figure 5). For example, (2)-epigallocatechin, (2)-
epicatechin and (2)-catechin showed almost no or very little
inhibition ((2)-epigallocatechin ca. 25% inhibition at 200 mM).
However, when (2)-epigallocatechin gallate (ca. 75% inhibition at
100 mM) and (2)-gallocatechin (ca. 53% inhibition at 100 mM)
were used as inhibitors, a much larger effect could be detected. A
possible explanation might be that all other catechins tested in this
study are non-gallic acid esterified compounds (Fig. 5). (2)-
Epigallocatechin and (2)-gallocatechin are diastereoisomers (Fig. 5)
from which (2)-gallocatechin showed a greater inhibition (Fig. 4).
The gallic acid esterified form of (2)-epigallocatechin, EGCG, is
the most potent substance tested so far, which may lead to the
assumption that the gallic acid ester form of (2)-gallocatechin, (2)-
gallocatechin gallate may exhibit an even greater inhibitory
potential than EGCG. Nevertheless, EGCG showed the highest
inhibition in this study and was an obvious choice for further
From cell culture experiments it is known that polyphenols like
EGCG and EGC trigger a rapid hydrogen peroxide generation in
various buffer systems. Concentrations up to 220 mM of hydrogen
peroxide generated by 200 mM EGCG (incubated for 3 h at 37uC)
in the buffer systems used could be detected. In contrast, addition
of human liver microsomes, NADPH and cortisone to the reaction
mixture resulted in about 12 mM hydrogen peroxide. A possible
explanation for this hydrogen peroxide preventing effect might be
the presence of peroxisomes in the microsomal fraction which
contain several peroxidases known to catalyze the reduction of
hydrogen peroxide to water. Further, due to the possibility that
hydrogen peroxide generated by catechins could be responsible for
the 11b-HSD1 inhibition observed in our study, we tested the
inhibitory effects of up to 300 mM hydrogen peroxide on cortisone
reduction. However, no inhibition of cortisol formation by both
human liver microsomes and purified human 11b-HSD1,
respectively, could be detected.
Figure 8. Dixon plot to characterize the inhibition type and to determine the Ki of EGCG on cortisone reduction in human liver
microsomes. The inset shows direct plotting of the same data.
11b-HSD1 Inhibition by Green Tea and EGCG
PLOS ONE | 6 January 2014 | Volume 9 | Issue 1 | e84468
Next, we determined the IC50-values of EGCG to inhibit the
conversion of cortisone to cortisol and vice versa by human liver
microsomes. The results indicate that the dehydrogenase activity
seems to be less affected by EGCG than the reducing activity
(reduction: IC50 = 57.99 mM; oxidation: IC50 = 131.20 mM; see
Figs. 6, 7).
As mentioned before, 11b-HSD1 reductase and dehydrogenase
activities are varying from tissue to tissue [25]. Moreover, recent
reports indicate the capability of cortisol oxidation by 11b-HSD1
in subcutaneous adipose tissues [40]. Hence, a shift in the
equilibrium towards cortisone may occur in vivo. In the past,
selectivity of inhibitors for 11b-HSD1 over 11b-HSD2 has
received most attention. In addition, effectiveness of inhibitors
should also consider a selectivity for cortisone reduction by 11b-
HSD1 over its cortisol to cortisone dehydrogenase reaction. This
assumption may be underpined by the fact that many selective
11b-HSD1 inhibitors failed in clinical trials [41].
Figure 9. Dixon plot to characterize the inhibition type and to determine the Ki of EGCG on cortisone reduction by purified 11b-
HSD1. The inset shows direct plotting of the same data.
Table 1. Inhibition constants of EGCG on cortisone reduction with human liver microsomes and purified human 11b-HSD1.
human liver microsomes purified human 11b-HSD1
Ki (non-linear regression) 22.68 mM 18.74 mM
Ki (estimated by Dixon-plot) 17.80 mM 20.93 mM
Data are derived from non-linear regression curves and Dixon-plots (Figs. 8–11).
11b-HSD1 Inhibition by Green Tea and EGCG
PLOS ONE | 7 January 2014 | Volume 9 | Issue 1 | e84468
A recently published paper about the inhibition of cortisol
production by EGCG in rat liver microsomes proposes a redox
shift in the lumen of the endoplasmic reticulum (ER) being
responsible for the EGCG dependent effect [42]. However, in our
present study we used purified 11b-HSD1 from human liver for
EGCG inhibition studies. Detailed kinetic analysis yielded a mixed
mode of EGCG on 11b-HSD1 inhibition with respect to cortisone.
Moreover, we were able to determine a Ki for EGCG of
18.74 mM using non-linear regression analysis, which is similar to
the Ki determined by using human liver microsomes
(Ki = 17.8 mM). As a consequence, our results indicate a direct
effect of EGCG to both purified and microsomal 11b-HSD1
rather than a EGCG-induced shift of NADPH to NADP in the ER
lumen. To strengthen our findings, EGCG was docked into the X-
ray crystal structure of human 11b-HSD1 (PDB: 2RBE) using
SwissDock [43]. The result of EGCG positioned into the active
site of 11b-HSD1 (Figure 11) support the direct binding of EGCG
into the substrate-binding pocket. EGCG forms a hydrogen bond
with Lys187 that is part of the catalytic triade of short-chain
dehydrogenases, suggesting a direct competition with binding of
the substrate and/or cofactor, respectively.
As reported by others [44], many microsomal (drug metabo-
lizing) enzymes (glyceraldehyde-3-phosphate dehydrogenase,
CYP1A1, CYP1A2, CYP2B1/2, CYP2E1, CYP3A, catechol-O-
methyltransferase and microsomal glutathione transferase 1) are
inhibited by EGCG. In these cases, the underlying mechanism of
inhibition was suspected to be protein aggregate formation in
EGCG-treated microsomes. To exclude protein aggregate forma-
tion by EGCG in our studies, 11b-HSD1 was incubated with
increasing EGCG concentrations of up to 100 mM for 3 h at 37uC
and then analyzed by Western Blot. From our results any
crosslinking of purified 11b-HSD1 by EGCG could be ruled
out, as no multimeric forms at higher molecular weight regions
were observed (Figure 10).
In conclusion, we provide evidence that aqueous extracts of tea
(Camellia sinensis) are able to inhibit cortisol formation by the
enzyme 11b-HSD1. From several abundant constitutents of tea,
the major phenolic compound EGCG could be identified as the
most potent inhibitor of human 11b-HSD1, with inhibition
constants of Ki = 22.68 mM in microsomes and Ki = 18.74 mM
Figure 10. Western Blot analysis of EGCG treated and EGCG
untreated purified human liver 11b-HSD1.
Figure 11. Binding model of EGCG docked to the active site of human 11b-HSD1. Shown is a binary complex of 11b-HSD1 (PDB: 2RBE) with
EGCG (blue) and NADPH (green). K187 belongs to the catalytic triade (yellow) and forms a predicted hydrogen bond with EGCG (distance: 2.1 A
11b-HSD1 Inhibition by Green Tea and EGCG
PLOS ONE | 8 January 2014 | Volume 9 | Issue 1 | e84468
for the purified enzyme, respectively. The mechanism of EGCG
inhibition is most likely a direct binding to the active site of 11b-
HSD1, which is supported by enzyme kinetic studies and a
computer aided docking model. Our results decipher the
mechanism by which catechins such as EGCG, or green tea in
general, have been successfully consumed for thousand of years for
general health benefits. These polyphenolic compounds may serve
as model structures for the development of novel agents to treat
the metabolic syndrome and related diseases.
Author Contributions
Conceived and designed the experiments: JH CS CL HJM. Performed the
experiments: CS CL. Analyzed the data: JH CS CL HJM. Contributed
reagents/materials/analysis tools: EM. Wrote the paper: JH HJM. Added
valuable points of discussion: JH CL CS HJM EM.
1. Macfarlan e (2004) The Empire of Tea. The Overlook Press.
2. Sang S, Lambert JD, Ho C-T, Yang CS (2011) The chemistry and
biotransformation of tea constituents. Pharmacol Res Off J Ital Pharmacol
Soc 64: 87–99. doi:10.1016/j.phrs.2011.02.007.
3. Nakachi K, Matsuyama S, Miyake S, Suganuma M, Imai K (2000) Preventive
effects of drinking green tea on cancer and cardiovascular disease: epidemio-
logical evidence for multiple targeting prevention. BioFactors Oxf Engl 13: 49–
4. Sato Y, Nakatsuka H, Watanabe T, Hisamichi S, Shimizu H, et al. (1989)
Possible contribution of green tea drinking habits to the prevention of stroke.
Tohoku J Exp Med 157: 337–343.
5. Setiawan VW, Zhang ZF, Yu GP, Lu QY, Li YL, et al. (2001) Protective effect
of green tea on the risks of chronic gastritis and stomach cancer. Int J Cancer J Int
Cancer 92: 600–604.
6. Sueoka N, Suganuma M, Sueoka E, Okabe S, Matsuyama S, et al. (2001) A new
function of green tea: prevention of lifestyle-related diseases. Ann N Y Acad Sci
928: 274–280.
7. Grove KA, Lambert JD (2010) Laboratory, epidemiological, and human
intervention studies show that tea (Camellia sinensis) may be useful in the
prevention of obesity. J Nutr 140: 446–453. doi:10.3945/jn.109.115972.
8. Cabrera C, Artacho R, Gime´nez R (2006) Beneficial effects of green tea–a
review. J Am Coll Nutr 25: 79–99.
9. Chacko SM, Thambi PT, Kuttan R, Nishigaki I (2010) Beneficial effects of green
tea: a literature review. Chin Med 5: 13. doi:10.1186/1749-8546-5-13.
10. Sae-tan S, Grove KA, Lambert JD (2011) Weight control and prevention of
metabolic syndrome by green tea. Pharmacol Res Off J Ital Pharmacol Soc 64:
146–154. doi:10.1016/j.phrs.2010.12.013.
11. Ihm S-H, Jang S-W, Kim O-R, Chang K, Oak M-H, et al. (201 2) Decaffeinated
green tea extract improves hypertension and insulin resistance in a rat model of
metabolic syndrome. Atherosclerosis 224: 377–383. doi:10.1016/j.atherosclerosis.
12. Thieleck e F, Boschmann M (2009) The potential role of green tea catechins in
the prevention of the metabolic syndrome - a review. Phytochemistry 70: 11–24.
13. Brown AL, Lane J, Coverly J, Stocks J, Jackson S, et al. (2009) Effects of dietary
supplementation with the green tea polyphenol epigallocatechin-3-gallate on
insulin resistance and associated metabolic risk factors: randomized controlled
trial. Br J Nutr 101: 886–894. doi:10.1017/S0007114508047727.
14. Maeda-Y amamoto M (2013) Human clinical studies of tea polyphenols in allergy
or life style-related diseases. Curr Pharm Des.
15. Ikeda I (2008) Multifunctional effects of green tea catechins on prevention of the
metabolic syndrome. Asia Pac J Clin Nutr 17 Suppl 1: 273–274.
16. Suzuki Y, Miyoshi N, Isemura M (2012) Health-promoting effects of green tea.
Proc Jpn Acad Ser B Phys Biol Sci 88: 88–101.
17. Bhagwat S (2011) USDA Database for the Flavonoid Contents of Selected
18. Harbowy ME, Balentine DA, Davies AP, Cai Y (1997) Tea Chemistry. Crit Rev
Plant Sci 16: 415–480. doi:10.1080/07352689709701956.
19. Balentine DA, Wiseman SA, Bouwens LC (1997) The chemistry of tea
flavonoids. Crit Rev Food Sci Nutr 37: 693–704. doi:10.1080/
20. Leung L, Birtwhistle R, Kotecha J, Hannah S, Cuthbertson S (2009) Anti-
diabetic and hypoglycaemic effects of Momordica charantia (bitter melon): a
mini review. Br J Nutr 102: 1703–1708. doi:10.1017/S0007114509992054.
21. Shen Y, Hu Y, Chen B, Yao S (2010) Screening of enzyme inhibitors from
traditional Chinese medicine. Comb Chem High Throughput Screen 13: 885–
22. Masuza ki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, et al. (2001) A
transgenic model of visceral obesity and the metabolic syndrome. Science 294:
2166–2170. doi:10.1126/science.1066285.
23. Blum A, Maser E (2003) Enzymology and molecular biology of glucocorticoid
metabolism in humans. Prog Nucleic Acid Res Mol Biol 75: 173–216.
24. Maser E, Vo¨lker B, Friebertsha¨user J (2002) 11 Beta-hydroxysteroid dehydro-
genase type 1 from human liver: dimerization and enzyme cooperativity support
its postulated role as glucocorticoid reductase. Biochemistry (Mosc) 41: 2459–
25. Tomlinson JW, Walker EA, Bujalska IJ, Drape r N, Lavery GG, et al. (2004)
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of
glucocorticoid response. Endocr Rev 25: 831–866. doi:10.1210/er.2003-0031.
26. White PC, Mune T, Agarwal AK (1997) 11 beta-Hydroxysteroid dehydrogenase
and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18: 135–
27. Wamil M, Seckl JR (2007) Inhibition of 11beta-hydroxysteroid dehydrogenase
type 1 as a promising therapeutic target. Drug Discov Today 12: 504–520.
28. Staab CA, Maser E (2010) 11beta-Hydroxysteroid dehydrogenase type 1 is an
important regulator at the interface of obesity and inflammation. J Steroid
Biochem Mol Biol 119: 56–72. doi:10.1016/j.jsbmb.2009.12.013.
29. Morton NM, Seckl JR (2008) 11beta-hydroxysteroid dehydrogenase type 1 and
obesity. Front Horm Res 36: 146–164. doi:10.1159/0000115363.
30. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, et al. (2005)
Adipocyte-specific glucocorticoid inactivation protects again st diet-induced
obesity. Diabetes 54: 1023–1031.
31. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, et al. (2004)
Metabolic synd rome without obesity: Hepatic overexpression of 11beta -
hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad
Sci U S A 101: 7088–7093. doi:10.1073/pnas.0305524101.
32. Kotelev tsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, et al. (1997)
11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated
glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress.
Proc Natl Acad Sci U S A 94: 14924–14929.
33. Morton NM, Holmes MC, Fie´vet C, Staels B, Tailleux A, et al. (2001) Improved
lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in
11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 276:
41293–41300. doi:10.1074/jbc.M103676200.
34. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, et al. (2004)
Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11
beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53: 931–
35. Blum A, Martin HJ, Maser E (2000) Human 11beta-hydroxysteroid dehydro-
genase 1/carbonyl reductase: recombinant expression in the yeast Pichia pastoris
and Escherichia coli. Toxicology 144: 113–120.
36. Blum A, Loerz C, Martin H-J, Staab-Weijnitz CA, Maser E (2012) Momordica
charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11b-
hydroxysteroid dehydrogenase type 1 inhibitor. J Steroid Biochem Mol Biol 128:
51–55. doi:10.1016/j.jsbmb.2011.09.003.
37. Halliwell B (2008) Are polyphenols antioxidants or pro-oxidants? What do we
learn from cell culture and in vivo studies? Arch Biochem Biophys 476: 107–112.
38. Long LH, Clement MV, Halliwell B (2000) Artifacts in cell culture: rapid
generation of hydrogen peroxide on addition of (2)-epigallocatechin, (2)-
epigallocatechin gallate, (+)-catechin, and quercetin to commonly used cell
culture media. Biochem Biophys Res Commun 273: 50–53. doi:10.1006/
39. Dringe n R, Kussmaul L, Hamprecht B (1998) Detoxification of exogenous
hydrogen peroxide and organic hydroperoxides by cultured astroglial cells
assessed by microtiter plate assay. Brain Res Brain Res Protoc 2: 223–228.
40. Hughes KA, Manolopoulos KN, Iqbal J, Cruden NL, Stimson RH, et al. (2012)
Recycling between cortisol and cortisone in human splanchnic, subcutaneous
adipose, and skeletal muscle tissues in vivo. Diabetes 61: 1357–1364.
41. Ge R, Huang Y, Liang G, Li X (2010) 11beta-hydroxysteroid dehydrog enase
type 1 inhibitors as promising therapeutic drugs for diabetes: status and
development. Curr Med Chem 17: 412–422.
42. Szele´nyi P, Re´ve´sz K, Konta L, Tu¨ tto˜ A, Mandl J, et al. (2013) Inhibition of
microsomal cortisol production by (2)-epigallocatechin-3-gallate through a
redox shift in the endoplasmic reticulum-A potential new target for treating
obesity-related diseases. BioFactors Oxf Engl. doi:10.1002/biof.1095.
43. Grosdidier A, Zoete V, Michielin O (2011) SwissDock, a protein-small molecule
docking web service based on EADock DSS. Nucleic Acids Res 39: W270–277.
44. Weng Z, Greenhaw J, Salminen WF, Shi Q (2012) Mechanisms for
epigallocatechin gallate induced inhibition of drug metabolizing enzymes in
rat liver microsomes. Toxicol Lett 214: 328–338. doi:10.1016/j.tox-
11b-HSD1 Inhibition by Green Tea and EGCG
PLOS ONE | 9 January 2014 | Volume 9 | Issue 1 | e84468
... Une étude récente a montré que des souris KO pour cette enzyme présentait une résistance aux effets cognitifs et émotionnels du stress chronique et ce à long terme, suggérant que les effets neurobiologiques du stress dépendent en grande partie des GC générés localement par la 11β-HSD1 dans différentes structures cérébrales (Wheelan et al., 2018a). La 11β-HSD2, quant à elle, possède exclusivement une activité déshydrogénase (Hintzpeter et al., 2014), c'est-à-dire qu'elle inactive le cortisol (ou la corticostérone) en cortisone (figure 4 ...
... Une partie de ces glucocorticoïdes passe la barrière placentaire et atteignent le foetus, ce qui peut engendrer des perturbations de l'activité de son axe HPA en cours de développement (Koehl et al., 1999). En condition physiologique le foetus est protégé contre les GC maternels par l'enzyme 11βHSD2 qui dégrade la corticostérone (ou le cortisol chez l'Homme) en un dérivé inactif (Hintzpeter et al., 2014). En revanche, un stress prénatal (stress de contention infligé à la mère par exemple) entraîne une réduction de l'expression de la 11βHSD2 et de son activité dans le placenta , ce qui participe à la hausse de GC chez le foetus et à la réactivité accrue de son axe HPA, qui se maintiennent à la naissance (Maccari et al., 1995). ...
... Figure 4 : Mécanisme d'activation et d'inactivation du cortisolLa 11β-HSD active la cortisone en cortisol, tandis que la 11β-HSD2 inactive le cortisol en cortisone (d'aprèsHintzpeter et al., 2014).MR concerne majoritairement le système limbique notamment l'HPC, l'amygdale, le septum et l'hypothalamus. Par contre, la distribution des GR est ubiquitaire avec une forte densité dans l'HPC et le PVN de l'hypothalamus (figure 5). ...
Le stress chronique est un phénomène universel qui concerne toutes les strates de la société, quels que soient l’âge, le sexe, le milieu social, les origines culturelles et géographiques. Néanmoins la vulnérabilité est variable selon l’âge d’exposition. Il est aujourd’hui avéré qu’une exposition chronique à un stress ou bien une exposition à un stress aigu intense chez l’enfant, voire même pendant la période périnatale, peut avoir des conséquences dramatiques sur le développement cérébral et peut engendrer un certain nombre de pathologies neuropsychiatriques plus tard au cours de la vie. Néanmoins, une plus forte résistance et une capacité de résilience apparaît à l’âge adulte se caractérisant notamment par une adaptabilité et la possibilité de retourner rapidement à un état initial après une exposition au stress. Toutefois, des travaux récents suggèrent qu’une seconde phase de vulnérabilité apparait en milieu de vie, période charnière durant laquelle certaines structures du système limbique commencent peu à peu à décliner. L’objectif de cette thèse a été ainsi dans un premier temps de mieux caractériser la nature des perturbations somatiques à court terme et des déficits comportementaux à long terme qui apparaissent suite à un stress chronique durant cette période charnière au cours de laquelle s’installe une vulnérabilité accrue aux stress. Pour répondre à cette première problématique, le modèle de stress chronique léger et imprédictible mis au point chez la souris a été utilisé. Les impacts à court terme ont été déterminés en analysant les troubles somatiques et endocriniens, puis ceux à long-terme (chez le sujet âgé), ont été déterminés en analysant les troubles comportementaux anxieux, dépressifs et cognitifs, caractéristiques du syndrome de stress. D’autre part, il s’agissait d’identifier les réorganisations épigénétiques associés au vieillissement et au stress chronique ayant eu lieu en milieu de vie. Nous nous sommes concentrés sur les perturbations de la marque permissive H3K9ac et la marque répressive H3K27me3 en fonction du vieillissement et du stress chronique à long terme. Enfin, une approche pharmacologique a été utilisée pour évaluer l’impact d’un traitement ciblant ces mécanismes épigénétiques sur les déficits comportementaux. Un traitement chronique de 3 semaines à base de butyrate de sodium (NaB) qui est un iHDAC, a été administré aux animaux après la phase de stress chronique, puis les évaluations comportementales ont été réalisé à long terme, chez les sujets âgés.
... μM (Feng et al. 2011). A catechin derivative, EGCG (35), from green tea showed moderate inhibitory effect against h-11β-HSD1 with an IC 50 of 57.99 μM (Hintzpeter et al. 2014). A cyclic tetrapeptide, penicopeptide A (268) isolated from the culture of endophytic fungus Penicillium commune of grape plant, Vitis vinifera, in rice, inhibited the activity of h-11β-HSD1 with an IC 50 of 9.07 μM ). ...
... Accumulating evidence strongly demonstrates that the enzyme 11β-HSD1 is expressed in high concentrations in subcutaneous adipose tissues of obese and type 2 diabetic patients, and is the marker of insulin resistance and abdominal fat deposition. EGCG strongly inhibited the activity of human 11β-HSD1 activity with an IC 50 value of 57.99 μM (reduction) and inhibition constant Ki of 22.68 and 18.74 μM for human liver microsomes and purified human 11β-HSD1, respectively (Hintzpeter et al. 2014). In diabetic vascular tissues, the elevated expression of vasoconstrictor factor, endothelin-1 (ET-1), causes restriction of vasorelaxation process of vascular endothelial cells in arteries by decreasing nitric oxide production from eNOS and leads to cardiovascular diseases. ...
Pre-diabetes is a stage that usually precedes the onset of type 2 diabetes with a slight increase in fasting glucose, between 5.6 and 6.9 mmol/L; decreased glucose tolerance, between 7.8 and 11 mmol/L; and glycated hemoglobin, between 5.5 and 6.4% (ADA 2020). These biochemical abnormalities are usually caused by defects in insulin secretion from pancreatic cells, low insulin activity, or both (Unwin et al. 2002). Pre-diabetes can eventually lead to type 2 diabetes, which is characterized by hyperglycemia due to the inability of cells to respond fully to insulin, or to be resistant to insulin. Insulin resistance is characterized by insulin inefficiency in promoting glucose uptake by tissues and low intracellular glucose concentration signals for increased insulin production by the pancreas. Over time, depleted pancreatic beta cells reduce or stop insulin production, further elevating blood glucose levels (>6.9 mmol/L), characteristic of the diabetes condition. According to epidemiological data, type 2 diabetes is common in the elderly, but its frequency has increased in children and young adults due to high rates of obesity, sedentary lifestyle, and unbalanced diet, with excess fat and sugar. All of these factors indicate that both type 1 and type 2 diabetes result from a combination of genetic predisposition and environmental triggers (IDF 2020). Type 2 diabetes symptoms are similar to those of type 1 diabetes, but they are difficult to be identified in the early stages due to the long pre-diagnosis process, and, therefore, up to one third of the population may not be diagnosed early (Bansal 2015; Kaur 2014; Buchanan et al. 2002). This can be detrimental for a favorable prognosis after a long period of latent disease, and complications such as retinopathy or ulcers in the lower limbs that do not heal may occur (Chiasson et al. 2002). Furthermore,visceral obesity common in overweight and obese patients is related to the local and systemic inflammatory process, closely linked to the development of these comorbidities (ADA 2020). Regarding the healthy population, individuals with pre-diabetes and diabetes have a higher risk over the time of developing cardiovascular disease, metabolic syndrome, and polycystic ovaries, in addition to higher morbidity and mortality rates (Bansal 2015; Kaur 2014). Considering the close relationship between pre-diabetes, obesity, and diet, it is important to examine the influence of intestinal microbiota in this context. Intestinal microbiota is characterized by a diverse community of bacteria responsible for influencing nutrient metabolism, immune responses, and resistance to infectious pathogens (Nicholson et al. 2012; Belkaid and Hand 2014; van Nood et al. 2013). In the diabetic population, the intestinal microbiota presents a pattern of dysbiosis, which can be the starting point for the evolution of pre-diabetes to type 2 diabetes and other chronic diseases (Pratley 2013; Ziemer et al. 2008; Tsui et al. 2008; Stefanakia et al. 2018). Current scientific evidence has shown that probiotics or prebiotics, including phenolic compounds, can play a widely recognized role in the regulation of the intestinal microbiota, altering microbial composition and the metabolism of the bacteria and host (Tsai et al. 2019; Wang et al. 2020). Based on these fundamentals, this chapter will address the intrinsic relationships between the consumption of probiotics and prebiotics in individuals with pre-diabetes and type 2 diabetes.
... μM (Feng et al. 2011). A catechin derivative, EGCG (35), from green tea showed moderate inhibitory effect against h-11β-HSD1 with an IC 50 of 57.99 μM (Hintzpeter et al. 2014). A cyclic tetrapeptide, penicopeptide A (268) isolated from the culture of endophytic fungus Penicillium commune of grape plant, Vitis vinifera, in rice, inhibited the activity of h-11β-HSD1 with an IC 50 of 9.07 μM ). ...
... Accumulating evidence strongly demonstrates that the enzyme 11β-HSD1 is expressed in high concentrations in subcutaneous adipose tissues of obese and type 2 diabetic patients, and is the marker of insulin resistance and abdominal fat deposition. EGCG strongly inhibited the activity of human 11β-HSD1 activity with an IC 50 value of 57.99 μM (reduction) and inhibition constant Ki of 22.68 and 18.74 μM for human liver microsomes and purified human 11β-HSD1, respectively (Hintzpeter et al. 2014). In diabetic vascular tissues, the elevated expression of vasoconstrictor factor, endothelin-1 (ET-1), causes restriction of vasorelaxation process of vascular endothelial cells in arteries by decreasing nitric oxide production from eNOS and leads to cardiovascular diseases. ...
The increased worldwide prevalence of pre-diabetes and diabetes, especially type 2 diabetes, requiring different strategies for their prevention and management. A new focus is the reversal of diabetes dysbiosis, a disruption of gut microbiota homeostasis, which is closely related to elevated blood glucose levels and altered metabolic parameters. In this sense, a balanced diet plays a key role, and, particularly, probiotic and prebiotic have shown a promising role. This chapter explored current knowledge on the potential of probiotic and prebiotic to modulate glucose homeostasis. We showed that the consumption of probiotics and prebiotics is a promising strategy with a beneficial impact on gut microbiota and glycemic control. Furthermore, specific probiotic strains, such as L. acidophilus, L. casei strain Shirota, and B. lactis Bb12, have demonstrated the ability to improve parameters related to pre-diabetes and type 2 diabetes. In addition, polyphenols are emerging as a new alternative in glycemic control through the production of short chain fat acids (SCFA) and decreased lipopolysaccharides (LPS) translocation that leads to metabolic endotoxemia. Finally, the ingestion of beneficial bacteria, and foods rich in fiber and polyphenols, or a combination of them, is a good strategy for the control of pre-diabetes and type 2 diabetes, but more studies are still needed, mainly clinical trials, for these strategies are improved and widely used.
... Significant changes in subjects treated with placebo were not observed. The interconversion of the inert cortisone to active cortisol is catalyzed by the microsomal enzyme 11β-HSD1 and thereby acts as a key for regulating the access of glucocorticoid hormones to the glucocorticoid receptor [41]. There were significant reductions of salivary cortisol/cortisone ratios which indicate 11-β HSD1 activity in the PE group only from day 0 to day 28 at all-time points: morning from a mean of 1.12 ± 0.31 to 0.81 ± 0.33 (p = 0.003), noon from 1.31 ± 0.25 to 1.02 ± 0.38 (p = 0.047) and evening from 1.39 ± 0.41 to 1.06 ± 0.46 (p = 0.045). ...
Full-text available
Pomegranates are known to possess anti-hypertensive, anti-atherogenic and cardioprotective effects mainly due to their pleiotropic effects on various cellular pathways, especially those triggered by oxidative stress. The aim of this study was to investigate the effect of natural standardized pomegranate (PE) extract on cardiovascular risk factors in 24 healthy volunteers who participated in a randomized, single-blind placebo-controlled study. There were 12 subjects in the PE group and 12 in the placebo group. Variables were measured at baseline and after 14 and 28 days of supplementation are anthropometry, BP, pulse wave velocity, fat and lean body mass, salivary and urinary cortisol, and cortisone, total phenolics, antioxidant capacity and lipid peroxidation. Urinary total phenolics excretion and antioxidant capacity were significantly increased after 14 and 28 days of PE intake. At day 28, there were also statistically significant decreases in systolic and diastolic blood pressure (BP), pulse wave velocity, body fat and fat mass, as well as an increase in lean body mass. Significant changes in the placebo group were not found. Glucocorticoid levels showed a significant decrease in saliva cortisol at day 28 (morning) in the PE group, and cortisol/cortisone ratio was significantly decreased following 28 days of PE intake at morning, noon, and evening. Urine free cortisol was significantly reduced at day 14. These findings suggest that pomegranate extract intake may improve antioxidant and oxidative stress status and play a beneficial role in the attenuation of some cardiovascular risk factors. Future studies should concentrate on overweight and older people.
... 11β-HSD1, by converting cortisone (inactive) to cortisol (active), contributes to the differentiation of adipocytes [176,180]. The polyphenolic compounds including flavonoids such as apigenin obtained from Matricaria chamomilla and quercetin from Brassica oleracea, isoflavonoid such as genistein isolated from Glycine max and catechins such as epigallocatechin-3-gallate (EGCG) extracted from Camellia sinensis have the crucial role in the inhibition of 11β-HSD1 expression, especially in the adipose tissues and inactivation of cortisol in the liver leading to improved glucose metabolism and insulin signaling ( Table 1) [48,181]. It has been revealed that 11β-HSD1 is centrally involved in cortisol metabolism, thus inhibition of 11β-HSD1 particularly in the adipose tissues may provide a therapeutic strategy for the management of diabesity (Fig. 2) [170]. ...
Obesity-associated diabetes mellitus, a chronic metabolic affliction accounting for 90% of all diabetic patients, has been affecting humanity extremely badly and escalating the risk of developing other serious disorders. It is observed that 0.4 billion people globally have diabetes, whose major cause is obesity. Currently, innumerable synthetic drugs like alogliptin and rosiglitazone are being used to get through diabetes, but they have certain complications, restrictions with severe side effects, and toxicity issues. Recently, the frequency of plant-derived phytochemicals as advantageous substitutes against diabesity is increasing progressively due to their unparalleled benefit of producing less side effects and toxicity. Of these phytochemicals, dietary polyphenols have been accepted as potent agents against the dual sword “diabesity”. These polyphenols target certain genes and molecular pathways through dual mechanisms such as adiponectin upregulation, cannabinoid receptor antagonism, free fatty acid oxidation, ghrelin antagonism, glucocorticoid inhibition, sodium-glucose cotransporter inhibition, oxidative stress and inflammation inhibition etc. which sequentially help to combat both diabetes and obesity. In this review, we have summarized the most beneficial natural polyphenols along with their complex molecular pathways during diabesity
... Hepatic CCAAT-enhancer binding proteinα (C/EBP-α) is the main transcription factor required for 11β-HSD1 mRNA expression found to increase by supplementation of TFAs and SFAs in the rat. The consumption of medicinal plants such as tea is reported to reduce 11β-HSD1 activity (Hintzpeter, Stapelfeld, Loerz, Martin, & Maser, 2014). About five compounds isolated from tea showed slight inhibitory effects on both human and mouse 11β-HSD1 activity (G. ...
Full-text available
Obesity is a metabolic disease associated with high morbidity and mortality worldwide. Previously we showed that Gum Arabic (GA) inhibited obesity in fed with diet-induced obesity. However, the mechanism underlying the mode of action is not fully elucidated. Here we aimed to identify the effects of GA on CCAAT-enhancer-binding protein- α (C/EBP- α) in mouse-fed diet-induced obesity. Thirty female CD-1 mice 90 days old were randomly divided into three groups (n=10). Mice were fed either a regular diet (control), a high-fat diet (HFD), or a high-fat diet containing 10% w/w GA (HFD+GA) for 15 weeks. Body weights, visceral adipose tissue (VAT), plasma lipid, blood glucose, plasma insulin, adiponectin, and leptin levels were measured. In addition, 11 β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and C/EBP- α gene mRNA expressions were measured, and 11β-HSD1 as well. Supplementation of GA significantly (P < 0.05) decreased body weight gain and VAT associated with decreases in blood glucose, total cholesterol LDL, and increased HDL concentrations. Likewise, administration of GA significantly (P < 0.05) decreased plasma Corticosterone (CORT) and leptin concentrations, whereas increased adiponectin compared to the control and HFD groups. In addition, GA administration significantly (P < 0.05) reduced the abundance of both hepatic 11β-HSD1 and C/EBP- α gene mRNA expression compared to the control and HFD groups. Supplementation of GA significantly (P < 0.05) down-regulated hepatic 11β-HSD1 protein expression compared to control and HFD groups. These findings indicate that GA consumption may be useful to prevent obesity through suppression of C/EBP- α gene expression.
... Various teas (Camellia sinensis (L)Kuntze ), tea particular polyphenolic agents were investigated for human liver microsomes and human purified 11 β-HSD1 for their probable antidiabetic action through reduction of cortisone by hampering action on 11 β-HSD1. 67 The polyphenol(-_ epigallocatechin gallate(EGCG) demonstrated, maximum robust hampering action on 11 β-HSD1((IC 50 value =57. 99 μMfor reduction; IC 50 value =131. 2 μMfor Oxidation). ...
Full-text available
There has been a significant escalation of type2 diabetes mellitus( T2DM), all over the world in particular more recently, secondary to population, age, obesity in addition to the sedentary life styles stranges. The determination as per the projections has been that 230 million people would be diabetic by the year2030. The properties of T2DM are dysfunctional pancreatic β cells function in addition to insulin liberation, hyperglycemia along with insulin resistance as well as recently, the epigenetics control pancreatic β cells differentiation has got emphasized as being implicated. Currently it is clear that various bioactive molecules, that are in plenty of amounts in plants that get utilized as foods or infusions, possess crucial part in histone modifications as well as DNA methylation, thus make up potential agents to work as epidrugs. Having earlier reviewed the epigenetic modes seen in DiabeticNephropathy so here we conducted a systematic review utilizing search engine pubmed, google scholar ;web of science; embase; Cochrane review library utilizing the MeSH terms like phytochemicals ;epidrugs; T2DM; epigenetics alterations inDM;Resveratrol; polyphenols; licorice; fenugreek;citrus fruits; green tea;ginger from 1990’still date in 2021. We found a total of 3050 articles out of which we selected 151 articles for this review. No meta-analysis was done. Thus we have summarized the epigenetic alterations seen in T2DM per se We have tried to review drugs like polyphenols, garlic, tea, resveratrol, anthrocyanins, liquorice, fenugreek that possess he capacity of avoidance or treatment of T2DM both in vivo, awa in vitro studies. The major observations, despite certain contradictory outcomes seem that these epidrugs possess roles to act either as complementary/replacement treatment for the usual oral hypoglycemic agents with negligible adverse actions. Actually these natural epidrugs seem to avoid or postpone the generation of disease, in addition to the morbidity that is correlated with the impairment of blood vessels, eyes as well as kidneys secondary to sustenance of hyperglycemia in case of patients with T2DM. Keywords: T2DM, hyperglycemia, epidrugs, epigenetics alterations, phytochemicals
The objective of this study was to evaluate the effect of grape seed extract (GSE) supplementation on growth performance, blood metabolites, hormone responses, and fecal volatile fatty acids (VFA) concentration in dairy calves during the summer months. Sixty Holstein female calves 3 d old and 40.6 ± 2.17 kg body weight (BW) were randomly divided into four groups (n = 15). GSE was given orally to the calves with milk daily at doses of 0 (CON), 25 (GSE1), 50 (GSE2), and 100 (GSE3) mg/kg BW. Calves were weighed at 15-day intervals and blood samples were taken on d 3, 33, and 63. Fecal samples were collected on d 33 and 63 of the study to evaluate VFA. Temperature humidity index (THI) values ranged from 73.2 to 87.4 throughout the study, and the study was terminated on d 63. Calves fed GSE2 had the highest (P < 0.01) average daily gain (ADG) between d 3-18 and 33-48 of the study, while the GSE3 group had the highest (P < 0.01) ADG between d 18-33 and 48-63. Moreover, calves fed GSE3 had the highest (P < 0.01) starter mixture intake over the entire study period. Serum non-esterified fatty acids (NEFA) concentrations decreased (P = 0.003) in calves fed GSE2 compared to the other groups. Plasma insulin concentration decreased (P < 0.001) in calves fed GSE3 compared to the other groups, however, increased (P < 0.01) in GSE1 and GSE2 groups until d 33. Plasma cortisol concentration decreased (P < 0.01) in GSE2 and GSE3 groups compared to the CON and GSE1 groups. Also, calves fed GSE2 and GSE had lower (P < 0.01) leptin concentration than the others (day 63). Calves fed GSE3 increased (P < 0.01) fecal total VFA, acetate, propionate, and valerate concentrations compared to other groups, whereas the lowest (P < 0.05) concentrations were observed in the GSE1 group. In summary, GSE supplementation caused a beneficial effect on energy metabolism, endocrine system, and colonic fermentation and thus improved growth performance in Holstein calves under heat stress.
Recently available drugs of synthetic origin in management of obesity and diabetes are costly and not affordable by poor people and have potential adverse side effects, and thereby these cause serious other complications among many obese and diabetic patients. As a result, some of these drugs have been withdrawn from the market. For this reason, most of the leading pharmaceutical industries have paid their attention for discovery of potential natural compounds with low-cost and minimal adverse effects for treatment of obesity and diabetes as an alternative strategy. In the earlier chapter, we have discussed that a large variety of natural resources, namely, dietary fruits, vegetables, grains, plants, seaweeds, edible and medicinal mushrooms, marine fishes and cucumbers, and microorganisms, have potential anti-obesity and antidiabetic effects. Their bioactive phytochemicals having diverse skeletal structures and belonging to different chemical classes, such as flavonoids, simple phenolics, lignans, stilbenoids, curcuminoids, tannins, alkaloids, terpenoids, steroids, saponins, organosulfurs, thiosugars, and polysaccharides. A growing body of evidence demonstrates that these natural products have multiple targets of action for prevention and treatment of obesity and diabetes. Most of these natural components exhibit hypolipidemic, hypoglycemic, antioxidant, and anti-inflammatory activities for improvement of insulin resistance, insulin secretion, and insulin action in insulin-responsive tissues for amelioration of lipid and glucose metabolic disorders in cellular and vivo models of obesity and diabetes. In this chapter, we address the pharmacology of some phytochemicals having potent anti-obesity and antidiabetic activity and their major natural sources and molecular targets.
Since the prehistoric times, at least 60,000 years back as per fossil records, humans have been using natural products, such as plants, animals, microorganisms, and marine organisms, in medicines to alleviate and treat diseases. The use of natural products as medicines must have a great challenge to early humans because when seeking food in forests and hills, early humans often consumed poisonous plants, which led them to vomiting, diarrhea, coma, or other toxic reaction-even death. Subsequently, they were able to develop knowledge about edible plant materials and to use many plants as natural medicines for treatment of diseases and ailments, which are the basis of traditional medicine. Such forms of traditional medicines, namely, traditional Chinese medicine (TCM), Indian Ayurveda, Greek-Arabic Unani, Japanese Kampo, and traditional Korean medicine, known as Sasang constitutional medicine (SCM) have been practiced worldwide for more than thousands of years and have blossomed into the present systems of modern medicines. The advancement of modern technology helped us to evaluate the pharmacology and mechanism of action of many medicinal herbs in treatment of diseases and to use them as cornerstones of modern medicine. In the historic year 1805, German pharmacist Friedrich Serturner isolated morphine from the opium plant, Papaver somniferum L., and laid the foundation of modern medicine. Subsequently, countless active natural molecules, known as phytochemicals have been separated from natural plant and microbial extracts, and many of them have potential anticancer, antihypertensive, hypolipidemic, antiobese, antidiabetic, antiviral, antileishmanial, and antimigraine medicative properties. These phytochemicals, which have evolved over millions of years, have a unique chemical structural diversity, which results in the diversity of their biological actions to alleviate and treat critical human diseases. A group of evidence advocates that a “multidrugs” and “multi-targets” approach would be more effective compared to a “single-drug” and “single-target” approach in the treatment of complex diseases like obesity, diabetes, cardiovascular disease, and cancer. Phytochemicals present in a single herb or in a herbal formulation can function alone or synergistically with other phytochemicals in a “multi-targets” approach to produce desired pharmacological effect in prevention and cure of complex diseases. The optimal efficacy of the herbal/polyherbal extract depends on its correct dosage containing the optimal concentration of bioactive phytochemical (s) and the method of preparing and processing of the herbal/polyherbal composition and the appropriate time of collection of plant parts. Therefore, the research on natural products is a thrust area for future research in drug discovery (Yuan et al. 2016). This chapter summarizes the current progress in the study of the antiobesity and antidiabetic potentials of natural products and their main bioactive phytochemicals, major molecular mechanisms in preventing and treating obesity and diabetes, and their associated complications.
Full-text available
Many previous epidemiological studies have revealed that green tea or green tea catechins contributed to the preveintion of lifestyle-related diseases. Several cohort studies on the relationship between green tea consumption and cardiovascular disease (CVD) risk/type 2 diabetes mellitus risk have been conducted. The results showed that green tea consumption (5 or more cups/day) was inversely associated with mortality from CVD and all causes. Within CVD mortality, the strongest inverse association was observed for stroke mortality. Furthermore, consumption of green tea, coffee, and total caffeine was associated with a reduced risk for type 2 diabetes. On the other hand, the analysis of randomized clinical trial (RCT) studies showed that the administration of green tea beverages or extracts resulted in significant reductions in serum total cholesterol and LDL-cholesterol concentrations, but had no apparent effect on HDL-cholesterol. Green tea reduced fasting blood glucose levels in a small intervention trial, although no improvements in HbA1c levels were seen. Continuous intake of green tea containing catechins and caffeine (5 or more cups per day) may be beneficial for body weight management, vascular disease risk reduction via LDL-cholesterol improvement, and type 2 diabetes risk reduction through the lowering of fasting blood glucose levels.
Full-text available
Glucocorticoid hormones, acting via nuclear receptors, regulate many metabolic processes, including hepatic gluconeogenesis. It recently has been recognized that intracellular glucocorticoid concentrations are determined not only by plasma hormone levels, but also by intracellular 11β-hydroxysteroid dehydrogenases (11β-HSDs), which interconvert active corticosterone (cortisol in humans) and inert 11-dehydrocorticosterone (cortisone in humans). 11β-HSD type 2, a dehydrogenase, thus excludes glucocorticoids from otherwise nonselective mineralocorticoid receptors in the kidney. Recent data suggest the type 1 isozyme (11β-HSD-1) may function as an 11β-reductase, regenerating active glucocorticoids from circulating inert 11-keto forms in specific tissues, notably the liver. To examine the importance of this enzyme isoform in vivo, mice were produced with targeted disruption of the 11β-HSD-1 gene. These mice were unable to convert inert 11-dehydrocorticosterone to corticosterone in vivo. Despite compensatory adrenal hyperplasia and increased adrenal secretion of corticosterone, on starvation homozygous mutants had attenuated activation of the key hepatic gluconeogenic enzymes glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, presumably, because of relative intrahepatic glucocorticoid deficiency. The 11β-HSD-1 −/− mice were found to resist hyperglycamia provoked by obesity or stress. Attenuation of hepatic 11β-HSD-1 may provide a novel approach to the regulation of gluconeogenesis.
The metabolic syndrome consists of a constellation of co-associated metabolic abnormalities such as insulin resistance, type 2 diabetes, dyslipidaemia, hypertension and visceral obesity. For many years endocrinologists have noted the striking resemblance between this disease state and that associated with Cushing’s syndrome. However, in the metabolic syndrome plasma cortisol levels tend to be normal or lower than in normal individuals. Nevertheless there is strong evidence that glucocorticoid action underlies metabolic disease, largely from rodent obesity models where removing glucocorticoids reverses obesity and its metabolic abnormalities. The apparent paradox of similar metabolic defects - despite the opposing plasma glucocorticoid profiles of Cushing’s and idiopathic metabolic syndrome - remained intriguing until the discovery that intracellular glucocorticoid reactivation was elevated in adipose tissue of obese rodents and humans. The enzyme that mediates this activation, conversion of cortisone (11-dehydrocorticosterone in rodents) to cortisol (corticosterone in rodents), locally within tissues is 11&Bgr; -hydroxysteroid dehydrogenase type 1 (11&Bgr; -HSD1). In order to determine whether elevated tissue 11&Bgr; -HSD1 contributed to obesity and metabolic disease, transgenic mice overexpressing 11&Bgr; -HSD1 in adipose tissue or liver were made. Adipose-selective 11&Bgr; -HSD1 transgenic mice exhibited elevated intra-adipose and portal, but not systemic corticosterone levels, abdominal obesity, hyperglycaemia, insulin resistance, dyslipidaemia and hypertension. In contrast, transgenic overexpression of 11&Bgr; -HSD1 in liver yielded an attenuated metabolic syndrome with mild insulin resistance, dyslipidaemia, hypertension and fatty liver, but not obesity or glucose intolerance. Together with early data using non-selective 11&Bgr; -HSD1 inhibitors to insulin sensitise humans, this corroborated the notion that the enzyme may be a good therapeutic target in the treatment of the metabolic syndrome. Further, a transgenic model of therapeutic 11&Bgr; -HSD1 inhibition, 11&Bgr; -HSD1 gene knock-out (11&Bgr; -HSD1-/-) mice, exhibited improved glucose tolerance, a ’cardioprotective’ lipid profile, reduced weight gain and visceral fat accumulation with chronic high-fat feeding. Recent evidence further suggests that high fat-mediated downregulation of adipose 11&Bgr; -HSD1 may be an endogenous pathway that underpins adaptive disease resistance in genetically predisposed mouse strains. This mechanism could feasibly make up a genetic component of innate obesity resistance in humans. The efficacy of 11&Bgr; -HSD1 inhibitors has recently been extended to include increased energy expenditure and reduction of arteriosclerosis, and therefore may be of significant therapeutic value in the metabolic syndrome, with complementary effects upon liver adipose tissue, muscle, pancreas and plaque-prone vessels.
Glucocorticoids (GC) play a fundamental role in controlling physiologic homeostasis and, when present in excess, can have a detrimental impact on glucose control, blood pressure and lipid levels. The oxidoreductase 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) mainly catalyzes the intracellular regeneration of active GCs (cortisol, corticosterone) from inert inactive 11-keto forms (cortisone) in liver, adipose tissue and brain, amplifying local GC action. Multiple lines of evidence have indicated that 11β-HSD1-mediated intracellular cortisol production may have a pathogenic role in type 2 diabetes and its co-morbidities. The 11β-HSD1 becomes a novel target for anti-type 2 diabetes drug developments, and inhibition of 11β-HSD1 offers a potential therapy to attenuate the type 2 diabetes. In the past several years, a lot of 11β-HSD1 inhibitors have been designed, synthesized, screened and discovered. Lowering intracellular glucocorticoid concentrations through administration of small molecule 11β-HSD1 selective inhibitors, significantly attenuates the signs and symptoms of disease in preclinical animal models and clinical trials of diabetes and metabolic syndrome. Among published inhibitors, DIO-902 from DiObex Inc. and INCB13739 from Incyte Inc. are now being investigated under Phase 2B clinical trials. However, the selectivity of current selective 11β-HSD1 inhibitors has been just focused on the difference between 11β-HSD1 and 11β-HSD2. They inhibit the bi-directional activities of 11β-HSD1, both 11β-HSD1 reductase (major) and oxidase (minor). In our lab, we have recently found novel chemicals that not only inhibit 11β-HSD1 reductase activity but also increase its oxidase activity without inhibition against 11β-HSD2. We propose that this dual modulation on 11β-HSD1 may provide a better therapeutic strategy for type 2 diabetes.
Conversion of cortisone to cortisol by 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) in the endoplasmic reticulum (ER) of the target cells is a major determinant of glucocorticoid action, and plays an important role in the development of obesity-related diseases. Inhibition of 11βHSD1 activity is, therefore, considered as a promising novel strategy for the treatment of metabolic syndrome and diabetes. Tea flavanols and their major representative, epigallocatechin gallate are known as antiobesity and antidiabetic agents. Their impacts on blood glucose level, hepatic glucose production, and insulin responsiveness resemble those observed on inhibition or depletion of 11βHSD1. We aimed to study the effect of epigallocatechin gallate on 11βHSD1 activity in ER-derived rat liver microsomes by measuring cortisone and cortisol with HPLC. Cortisol production was efficiently suppressed in a concentration dependent manner in intact microsomal vesicles. However, this effect was abolished by membrane permeabilization; and the three proteins involved in the overall process (11βHSD1, hexose 6-phosphate dehydrogenase, and glucose 6-phosphate transporter) were not or only mildly affected. Further investigation revealed the oxidation of luminal NADPH to NADP(+) , which attenuates cortisone reduction and favors cortisol oxidation in this compartment. Such a redox shift in the ER lumen might contribute to the beneficial health effects of tea flavanols and should be regarded as a promising strategy for the development of novel selective 11βHSD1 inhibitors to treat obesity-related diseases. © 2013 BioFactors, 2013.
Epigallocatechin gallate (EGCG) inhibits drug metabolizing enzymes by unknown mechanisms. Here we examined if the inhibition is due to covalent-binding of EGCG to the enzymes or formation of protein aggregates. EGCG was incubated with rat liver microsomes at 1-100μM for 30min. The EGCG-binding proteins were affinity purified using m-aminophenylboronic acid agarose and probed with antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH), actin, cytochrome P450 (CYP) 1A1, CYP1A2, CYP2B1/2, CYP2E1, CYP3A, catechol-O-methyltransferase (COMT) and microsomal glutathione transferase 1 (MGST1). All but actin and soluble COMT were positively detected at ≥1μM EGCG, indicating EGCG selectively bound to a subset of proteins including membrane-bound COMT. The binding correlated well with inhibition of CYP activities, except for CYP2E1 whose activity was unaffected despite evident binding. The antioxidant enzyme MGST1, but not cytosolic GSTs, was remarkably inhibited, providing novel evidence supporting the pro-oxidative effects of EGCG. When microsomes incubated with EGCG were probed on Western blots, all but the actin and CYP2E1 antibodies showed a significant reduction in binding at ≥1μM EGCG, suggesting that a fraction of the indicated proteins formed aggregates that likely contributed to the inhibitory effects of EGCG but were not recognizable by antibodies against the intact proteins. This raised the possibility that previous reports on EGCG regulating protein expression using GAPDH as a reference should be revisited for accuracy. Remarkable protein aggregate formation in EGCG-treated microsomes was also observed by analyzing Coomassie Blue-stained SDS-PAGE gels. EGCG effects were partially abolished in the presence of 1mM glutathione, suggesting they are particularly relevant to the in vivo conditions when glutathione is depleted by toxicant insults.
Oxidative stress and endothelial dysfunction are closely associated with hypertension and insulin resistance (IR) in metabolic syndrome (MetS). It is still controversial whether green tea extract (GTE) may have blood pressure (BP) lowering effect. Decaffeinated GTE might be presumed to have strong antioxidative effect and BP-lowering effect as compared with catechins. Thus we investigated whether decaffeinated-GTE could attenuate hypertension and IR by improving endothelial dysfunction and reducing oxidative stress in a rat model of MetS. 20 Otsuka Long-Evans Tokushima Fatty (OLETF) rats at 13 weeks old, MetS rats, were randomized into a saline treated group (OLETF; n = 10) and a group treated with decaffeinated-GTE (25 mg/kg/day) (GTE-OLETF; n = 10). Intraperitoneal glucose tolerance tests and BP measurements were performed at 13 and 25 weeks. Decaffeinated-GTE significantly reduced BP (OLETF vs. GTE-OLETF; 130 ± 7 vs. 121 ± 3 mmHg, p = 0.01), fasting/postprandial 2 h glucose (141 ± 18/159 ± 13 vs. 115 ± 7/132 ± 16 mg/dL, p = 0.009/0.002) and insulin levels (4.8 ± 2.3 vs. 2.4 ± 1.3 ng/mL, p < 0.001). Decaffeinated-GTE significantly reduced vascular reactive oxygen species (ROS) formation and NADPH oxidase activity, and improved endothelium dependent relaxation in the thoracic aorta of OLETF rats. Decaffeinated-GTE also suppressed the expression of p47 and p22phox (NADPH oxidase subunits) in the immunohistochemical staining, and stimulated phosphorylation of endothelial nitric oxide synthase (eNOS) and Akt in the immunoblotting of aortas. Decaffeinated-GTE reduced the formation of ROS and NADPH oxidase activity and stimulated phosphorylation of eNOS and Akt in the aorta of a rat model of MetS, which resulted in improved endothelial dysfunction and IR, and eventually lowered BP.